完全置換型人工心臓:医療機器パイプライン分析

◆英語タイトル:Total Artificial Heart - Medical Devices Pipeline Assessment, 2019
◆商品コード:GDT20FB0131
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年12月
◆ページ数:68
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD7,500 ⇒換算¥825,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Total Artificial Heart – Medical Devices Pipeline Assessment, 2019
Summary

GlobalData’s Medical Devices sector report, “Total Artificial Heart – Medical Devices Pipeline Assessment, 2019″ provides an overview of Total Artificial Heart currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Total Artificial Heart pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Total Artificial Heart under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Total Artificial Heart and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Total Artificial Heart under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

Table of Contents
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Total Artificial Heart Overview 6
3 Products under Development 7
3.1 Total Artificial Heart – Pipeline Products by Stage of Development 7
3.2 Total Artificial Heart – Pipeline Products by Territory 8
3.3 Total Artificial Heart – Pipeline Products by Regulatory Path 9
3.4 Total Artificial Heart – Pipeline Products by Estimated Approval Date 10
3.5 Total Artificial Heart – Ongoing Clinical Trials 11
4 Total Artificial Heart – Pipeline Products under Development by Companies 12
4.1 Total Artificial Heart Companies – Pipeline Products by Stage of Development 12
4.2 Total Artificial Heart – Pipeline Products by Stage of Development 13
5 Total Artificial Heart Companies and Product Overview 14
5.1 Abiomed Inc Company Overview 14
5.1.1 Abiomed Inc Pipeline Products & Ongoing Clinical Trials Overview 14
5.2 BiVacor Pty Ltd Company Overview 15
5.2.1 BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 15
5.3 Carmat SAS Company Overview 16
5.3.1 Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview 16
5.4 Cleveland Clinic Lerner College of Medicine Company Overview 20
5.4.1 Cleveland Clinic Lerner College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 20
5.5 Cleveland Heart Inc Company Overview 22
5.5.1 Cleveland Heart Inc Pipeline Products & Ongoing Clinical Trials Overview 22
5.6 Foster-Miller Inc (Inactive) Company Overview 23
5.6.1 Foster-Miller Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 23
5.7 Indian Institute of Technology Kharagpur Company Overview 24
5.7.1 Indian Institute of Technology Kharagpur Pipeline Products & Ongoing Clinical Trials Overview 24
5.8 Lausanne University Hospital Company Overview 25
5.8.1 Lausanne University Hospital Pipeline Products & Ongoing Clinical Trials Overview 25
5.9 OregonHeart Inc (Inactive) Company Overview 26
5.9.1 OregonHeart Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 26
5.10 ReliantHeart, Inc. Company Overview 27
5.10.1 ReliantHeart, Inc. Pipeline Products & Ongoing Clinical Trials Overview 27
5.11 Scandinavian Real Heart AB Company Overview 28
5.11.1 Scandinavian Real Heart AB Pipeline Products & Ongoing Clinical Trials Overview 28
5.12 Syncardia Systems LLC Company Overview 29
5.12.1 Syncardia Systems LLC Pipeline Products & Ongoing Clinical Trials Overview 29
5.13 TEDA International Cardiovascular Hospital Company Overview 36
5.13.1 TEDA International Cardiovascular Hospital Pipeline Products & Ongoing Clinical Trials Overview 36
5.14 University of Tokyo Company Overview 37
5.14.1 University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview 37
5.15 Yale University Company Overview 38
5.15.1 Yale University Pipeline Products & Ongoing Clinical Trials Overview 38
6 Total Artificial Heart- Recent Developments 39
6.1 Nov 27, 2019: CARMAT appoints Alexandre Eleonore as director of manufacturing 39
6.2 Nov 19, 2019: CARMAT granted authorization to resume the PIVOTAL study in the Czech Republic 39
6.3 Nov 13, 2019: Micron Solutions reports 2019 third quarter results 40
6.4 Nov 06, 2019: CARMAT: the feedback after 6 years and 8 months of cumulative support shows a constant improvement in the clinical outcomes of patients in the PIVOTAL study 40
6.5 Oct 31, 2019: Abiomed announces Q2 FY 2020 revenue of $205 million and 29.4% operating margin 41
7 Appendix 65
7.1 Methodology 65
7.2 About GlobalData 68
7.3 Contact Us 68
7.4 Disclaimer 68

List of Tables
Table 1: Total Artificial Heart - Pipeline Products by Stage of Development
Table 2: Total Artificial Heart - Pipeline Products by Territory
Table 3: Total Artificial Heart - Pipeline Products by Regulatory Path
Table 4: Total Artificial Heart - Pipeline Products by Estimated Approval Date
Table 5: Total Artificial Heart - Ongoing Clinical Trials
Table 6: Total Artificial Heart Companies - Pipeline Products by Stage of Development
Table 7: Total Artificial Heart - Pipeline Products by Stage of Development
Table 8: Abiomed Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: AbioCor II - Product Status
Table 10: AbioCor II - Product Description
Table 11: BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 12: BiVACOR Device - Product Status
Table 13: BiVACOR Device - Product Description
Table 14: Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview
Table 15: Artificial Heart - Product Status
Table 16: Artificial Heart - Product Description
Table 17: Carmat SAS - Ongoing Clinical Trials Overview
Table 18: Artificial Heart - Carmat Total Artificial Heart Early Feasibility Study
Table 19: Artificial Heart - Clinical Evaluation of the Carmat Total Artificial Heart for Patients with Advanced Heart Failure
Table 20: Cleveland Clinic Lerner College of Medicine Pipeline Products & Ongoing Clinical Trials Overview
Table 21: Continuous-Flow Total Artificial Heart - Product Status
Table 22: Continuous-Flow Total Artificial Heart - Product Description
Table 23: Pediatric Continuous-Flow Total Artificial Heart - Product Status
Table 24: Pediatric Continuous-Flow Total Artificial Heart - Product Description
Table 25: Cleveland Heart Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 26: SmartHeart TAH - Product Status
Table 27: SmartHeart TAH - Product Description
Table 28: Foster-Miller Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 29: MagScrew Total Artificial Heart - Product Status
Table 30: MagScrew Total Artificial Heart - Product Description
Table 31: Indian Institute of Technology Kharagpur Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Artificial Heart - Product Status
Table 33: Artificial Heart - Product Description
Table 34: Lausanne University Hospital Pipeline Products & Ongoing Clinical Trials Overview
Table 35: RollingHeart - Product Status
Table 36: RollingHeart - Product Description
Table 37: OregonHeart Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 38: Next Generation Total Artificial Heart - Product Status
Table 39: Next Generation Total Artificial Heart - Product Description
Table 40: ReliantHeart, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 41: Pulse Less Total Artificial Heart - Product Status
Table 42: Pulse Less Total Artificial Heart - Product Description
Table 43: Scandinavian Real Heart AB Pipeline Products & Ongoing Clinical Trials Overview
Table 44: Total Artificial Heart - Product Status
Table 45: Total Artificial Heart - Product Description
Table 46: Syncardia Systems LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 47: SynCardia 50cc Temporary Total Artificial Heart - Adult Bridge To Transplant - Product Status
Table 48: SynCardia 50cc Temporary Total Artificial Heart - Adult Bridge To Transplant - Product Description
Table 49: SynCardia 50cc Temporary Total Artificial Heart - Destination Therapy - Product Status
Table 50: SynCardia 50cc Temporary Total Artificial Heart - Destination Therapy - Product Description
Table 51: SynCardia 50cc Temporary Total Artificial Heart - Pediatric Bridge To Transplant - Product Status
Table 52: SynCardia 50cc Temporary Total Artificial Heart - Pediatric Bridge To Transplant - Product Description
Table 53: SynCardia 70cc Temporary Total Artificial Heart - Destination Therapy - Product Status
Table 54: SynCardia 70cc Temporary Total Artificial Heart - Destination Therapy - Product Description
Table 55: Syncardia Systems LLC - Ongoing Clinical Trials Overview
Table 56: SynCardia 70cc Temporary Total Artificial Heart - Destination Therapy - SynCardia 70cc Temporary Total Artificial Heart (TAH-t) for Destination Therapy (DT)
Table 57: SynCardia 50cc Temporary Total Artificial Heart - Adult Bridge To Transplant - SynCardia 50cc Temporary Total Artificial Heart (TAH-t) as a Bridge to Transplant
Table 58: TEDA International Cardiovascular Hospital Pipeline Products & Ongoing Clinical Trials Overview
Table 59: Artificial Heart - Product Status
Table 60: Artificial Heart - Product Description
Table 61: University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview
Table 62: Helical Flow Total Artificial Heart - Product Status
Table 63: Helical Flow Total Artificial Heart - Product Description
Table 64: Yale University Pipeline Products & Ongoing Clinical Trials Overview
Table 65: Corisma - Product Status
Table 66: Corisma - Product Description
Table 67: Glossary

List of Figures
Figure 1: Total Artificial Heart - Pipeline Products by Stage of Development
Figure 2: Total Artificial Heart - Pipeline Products by Territory
Figure 3: Total Artificial Heart - Pipeline Products by Regulatory Path
Figure 4: Total Artificial Heart - Pipeline Products by Estimated Approval Date
Figure 5: Total Artificial Heart - Ongoing Clinical Trials

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[完全置換型人工心臓:医療機器パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆